Dr. Naomi Balzer Haas Interprets the 5-Year Follow-up Updated Results of KEYNOTE-564
KEYNOTE-564 is the first global phase III clinical trial of adjuvant immunotherapy for renal cell carcinoma to achieve positive results. At the 2025 ASCO annual meeting, Dr. Naomi Balzer Haas from the Abramson Cancer Center, University of Pennsylvania presented the updated DFS (Disease-Free Survival) and OS (Overall Survival) results from the 5-year follow-up of the study. Oncology Frontier invited Dr. Naomi Balzer Haas to interpret the results at the conference site as follows.
ASCO 2025 | R-ALPS Trial by Dr. Ming Chen Proposes Dual-Maintenance Path for NSCLC
Editor’s Note: Since the PACIFIC trial established sequential immunotherapy following chemoradiotherapy as the standard treatment for unresectable stage III non-small cell lung cancer (NSCLC), improving upon this strategy has become…
ASCO 2025 | Dr. Jie Wang Presents China’s First PD-L1–Targeted ADC Trial Results
Editor’s Note: The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 30 to June 3 in Chicago. As the world’s leading oncology conference, this year’s…
ASCO 2025 | Dr. Li Zhang: ADC Breakthroughs in Lung Cancer Reflect the Promise of Precision Oncology
Editor’s Note: The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 30 to June 3 in Chicago, USA. Recognized as the largest and most prestigious…
ASCO 2025 | Dr. Hongbing Liu: Two-Cycle Chemotherapy Plus Immunotherapy Offers New Hope for Elderly Patients with Advanced Lung Cancer
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world’s most influential oncology conferences, was held in Chicago from May 30 to June 3. This year, a study led by Dr. Hongbing Liu from the Second Affiliated Hospital of Nanjing Medical University, in collaboration with the Jinling Clinical Medical College team, was selected for poster presentation (Abstract #8548). The research, titled "Camrelizumab Combined with Two-Cycle Chemotherapy as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Dual-Arm, Single-Center, Phase II Study", addresses a critical clinical question: Can the duration of chemotherapy be safely reduced? The study offers important insights for personalized treatment strategies in elderly NSCLC patients. Below is an in-depth discussion with Dr. Liu on the key findings.
ASCO 2025 | Dr. Li Zhang’s OptiTROP-Lung03 Study Showcased in Oral Presentation: Sacituzumab Tirumotecan Emerges as a Breakthrough in Overcoming EGFR-Mutant NSCLC Resistance
Sacituzumab tirumotecan, a novel TROP2-targeting antibody-drug conjugate (ADC) developed in China, has demonstrated promising therapeutic potential across multiple tumor types, including lung and breast cancer. At the 2025 ASCO Annual Meeting, a pivotal Phase II trial—OptiTROP-Lung03, led by Dr. Li Zhang of the Sun Yat-sen University Cancer Center—was selected for an oral presentation, marking a significant step for domestically developed TROP2-ADC therapy in tackling resistance in EGFR-mutant non-small cell lung cancer (NSCLC). With this presentation, Dr. Zhang brings Chinese innovation to the global oncology stage.